{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:19:31Z","timestamp":1774325971278,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Catatonia is characterized by psychomotor alterations and reduced contact with the environment. Initially linked to schizophrenia, it also occurs in mood disorders or organic conditions. In children, catatonia remains poorly delineated, despite dramatically increasing the risk of premature death. As data on pediatric drug-induced catatonia bears many uncertainties, we aimed to characterize its age-dependent patterns, using real-world data from the WHO safety database (VigiBase\u00ae).VigiBase\u00ae was queried for all reports of catatonia registered up to December 8th 2022. Reports involving patients &lt;18 years were classified into 3 groups: \u226423 months, 2\u201311 years, and 12\u201317 years. Disproportionality analyses relied on the Reporting Odds Ratio (ROR), and the positivity of the lower end of the 95% confidence interval of the Information Component (IC) was required to suspect a signal. Catatonia was evoked in 421 pediatric reports. In infants, vaccines were leading. In children, the main signals involved haloperidol (ROR 104.3; 95% CI 45.6\u2013238.5), ondansetron (ROR 40.5; 95% CI 16.5\u201399.5), and ciclosporin (ROR 27.4; 95% CI 13.8\u201354.1). In adolescents, chlorpromazine (ROR 199.1; 95% CI 134.8\u2013294.1), benzatropine (ROR 193; 95% CI 104.1\u2013361.6), and olanzapine (ROR 135.7; 95% CI 104.6\u2013175.9) reached the highest RORs. In infants, catatonia was related to vaccines, it was ascribed to multiple drugs in children, and mainly to psychotropic drugs in adolescents. Less suspected drugs, such as ondansetron, were highlighted. Despite limitations inherent in spontaneous reporting systems, this study supports that a careful anamnesis is warranted to separate catatonia associated with medical conditions from drug-induced catatonia in pediatric patients.<\/jats:p>","DOI":"10.1007\/s00787-023-02234-4","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T16:01:55Z","timestamp":1686585715000},"page":"1383-1393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-related catatonia in youths: real-world insights from the WHO Safety Database"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-2339","authenticated-orcid":false,"given":"Diane","family":"Merino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-6966","authenticated-orcid":false,"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Lavrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-0965","authenticated-orcid":false,"given":"Florence","family":"Askenazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-6981","authenticated-orcid":false,"given":"Susanne","family":"Th\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8126","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-530X","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"2234_CR1","volume-title":"Catatonia or the tension insanity","author":"K Kahlbaum","year":"1874","unstructured":"Kahlbaum K (1874) Catatonia or the tension insanity. Verlag August Hirshwald, Berlin"},{"key":"2234_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0957154X9500602205","volume":"6","author":"JC Goldar","year":"1995","unstructured":"Goldar JC, Starkstein SE (1995) Karl Ludwig Kahlbaum\u2019s concept of catatonia. Hist Psychiatry 6:201\u2013207","journal-title":"Hist Psychiatry"},{"key":"2234_CR3","volume-title":"Catatonia","author":"JP Burrow","year":"2022","unstructured":"Burrow JP, Spurling BC, Marwaha R (2022) Catatonia. StatPearls Publishing, StatPearls"},{"key":"2234_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.schres.2013.04.034","volume":"150","author":"R Tandon","year":"2013","unstructured":"Tandon R, Heckers S, Bustillo J, Barch DM, Gaebel W, Gur RE et al (2013) Catatonia in DSM-5. Schizophr Res 150:26\u201330","journal-title":"Schizophr Res"},{"key":"2234_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1440-1819.2003.01092.x","volume":"57","author":"K Takaoka","year":"2003","unstructured":"Takaoka K, Takata T (2003) Catatonia in childhood and adolescence. Psychiatry Clin Neurosci 57:129\u2013137","journal-title":"Psychiatry Clin Neurosci"},{"key":"2234_CR6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.schres.2016.06.020","volume":"176","author":"X Benarous","year":"2016","unstructured":"Benarous X, Consoli A, Raffin M, Bodeau N, Giannitelli M, Cohen D et al (2016) Validation of the Pediatric Catatonia Rating Scale (PCRS). Schizophr Res 176:378\u2013386","journal-title":"Schizophr Res"},{"key":"2234_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.schres.2009.04.021","volume":"113","author":"F Cornic","year":"2009","unstructured":"Cornic F, Consoli A, Tanguy M-L, Bonnot O, P\u00e9risse D, Tordjman S et al (2009) Association of adolescent catatonia with increased mortality and morbidity: evidence from a prospective follow-up study. Schizophr Res 113:233\u2013240","journal-title":"Schizophr Res"},{"key":"2234_CR8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1440-1614.2003.01125.x","volume":"37","author":"A Thakur","year":"2003","unstructured":"Thakur A, Jagadheesan K, Dutta S, Sinha VK (2003) Incidence of catatonia in children and adolescents in a paediatric psychiatric clinic. Aust N Z J Psychiatry 37:200\u2013203","journal-title":"Aust N Z J Psychiatry"},{"key":"2234_CR9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.schres.2005.01.014","volume":"76","author":"D Cohen","year":"2005","unstructured":"Cohen D, Nicolas J-D, Flament MF, P\u00e9risse D, Dubos P-F, Bonnot O et al (2005) Clinical relevance of chronic catatonic schizophrenia in children and adolescents: Evidence from a prospective naturalistic study. Schizophr Res 76:301\u2013308","journal-title":"Schizophr Res"},{"key":"2234_CR10","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.878173","volume":"13","author":"J Luccarelli","year":"2022","unstructured":"Luccarelli J, Kalinich M, Fernandez-Robles C, Fricchione G, Beach SR (2022) The incidence of catatonia diagnosis among pediatric patients discharged from General Hospitals in the United States: a Kids\u2019 Inpatient Database Study. Front Psychiatry 13:878173","journal-title":"Front Psychiatry"},{"key":"2234_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10803-020-04531-2","volume":"51","author":"A Shillington","year":"2021","unstructured":"Shillington A, Lamy M, Vawter-Lee M, Erickson C, Saal H, Comoletti D et al (2021) Case report: is catatonia a clinical feature of the natural progression of NLGN2-related neurodevelopmental disorder? J Autism Dev Disord 51:371\u2013376","journal-title":"J Autism Dev Disord"},{"issue":"22","key":"2234_CR12","first-page":"00374","volume":"S0920\u20139964","author":"S Walther","year":"2022","unstructured":"Walther S, Nadesalingam N, Nuoffer M, Kyrou A, W\u00fcthrich F, Lefebvre S (2022) Structural alterations of the motor cortex and higher order cortical areas suggest early neurodevelopmental origin of catatonia in schizophrenia. Schizophr Res S0920\u20139964(22):00374\u20137","journal-title":"Schizophr Res"},{"key":"2234_CR13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pediatrneurol.2010.07.001","volume":"43","author":"DM Dhossche","year":"2010","unstructured":"Dhossche DM, Wachtel LE (2010) Catatonia is hidden in plain sight among different pediatric disorders: a review article. Pediatric Neurol 43:307\u2013315","journal-title":"Pediatric Neurol"},{"key":"2234_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1542\/peds.63.4.677","volume":"63","author":"BJ Sullivan","year":"1979","unstructured":"Sullivan BJ, Dickerman JD (1979) Steroid-associated catatonia: report of a case. Pediatrics 63:677\u2013679","journal-title":"Pediatrics"},{"key":"2234_CR15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/01.jcp.0000280309.73742.aa","volume":"27","author":"P Desarkar","year":"2007","unstructured":"Desarkar P, Das A, Das B, Sinha VK (2007) Lithium toxicity presenting as catatonia in an adolescent girl. J Clin Psychopharmacol 27:410","journal-title":"J Clin Psychopharmacol"},{"key":"2234_CR16","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1038\/s41380-021-01158-2","volume":"26","author":"D Hirjak","year":"2021","unstructured":"Hirjak D, Sartorius A, Kubera KM, Wolf RC (2021) Antipsychotic-induced catatonia and neuroleptic malignant syndrome: the dark side of the moon. Mol Psychiatry 26:6112\u20136114","journal-title":"Mol Psychiatry"},{"key":"2234_CR17","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1097\/RHU.0000000000001481","volume":"27","author":"EF Beil","year":"2021","unstructured":"Beil EF, Vora SS (2021) Malignant catatonia after antipsychotic and high-dose steroid use in a teenager with neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol 27:S394\u2013S395","journal-title":"J Clin Rheumatol"},{"key":"2234_CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.schres.2017.07.028","volume":"200","author":"X Benarous","year":"2018","unstructured":"Benarous X, Raffin M, Ferrafiat V, Consoli A, Cohen D (2018) Catatonia in children and adolescents: new perspectives. Schizophr Res 200:56\u201367","journal-title":"Schizophr Res"},{"key":"2234_CR19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.encep.2020.09.002","volume":"47","author":"JP Lucchelli","year":"2021","unstructured":"Lucchelli JP, Kourakou S, Hasler G, Hilal R (2021) Clozapine withdrawal catatonia in a young schizophrenic man. L\u2019Enc\u00e9phale 47:396\u2013398","journal-title":"L\u2019Enc\u00e9phale"},{"key":"2234_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-018-0192-9","volume":"8","author":"M Lander","year":"2018","unstructured":"Lander M, Bastiampillai T, Sareen J (2018) Review of withdrawal catatonia: what does this reveal about clozapine? Transl Psychiatry 8:1\u201315","journal-title":"Transl Psychiatry"},{"key":"2234_CR21","doi-asserted-by":"crossref","first-page":"41538","DOI":"10.4088\/PCC.21cr03135","volume":"24","author":"A Sidana","year":"2022","unstructured":"Sidana A, Goel V (2022) Benzodiazepine withdrawal catatonia: a diagnostic intervention. Prim Care Companion CNS Disord 24:41538","journal-title":"Prim Care Companion CNS Disord"},{"key":"2234_CR22","first-page":"409","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M (2008) VigiBase, the WHO Global ICSR Database System: basic facts. Ther Innov Regul Sci 42:409\u2013419","journal-title":"Ther Innov Regul Sci"},{"key":"2234_CR23","unstructured":"Uppsala Monitoring Centre. About VigiBase. https:\/\/who-umc.org\/vigibase\/. Accessed 26 September 2022"},{"key":"2234_CR24","unstructured":"Centre UM. Uppsala Monitoring Centre. https:\/\/who-umc.org\/. Accessed 28 April 2022"},{"key":"2234_CR25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00002018-200528100-00003","volume":"28","author":"JK Aronson","year":"2005","unstructured":"Aronson JK, Ferner RE (2005) Clarification of terminology in drug safety. Drug Saf 28:851\u2013870","journal-title":"Drug Saf"},{"key":"2234_CR26","first-page":"316","volume":"71","author":"S Gautron","year":"2018","unstructured":"Gautron S, Wentzell J, Kanji S, Nguyen T, Kobewka DM, MacDonald E (2018) Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting. Can J Hosp Pharm 71:316\u2013323","journal-title":"Can J Hosp Pharm"},{"key":"2234_CR27","unstructured":"FDA. CFR - Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=312.32. Accessed 29 April 2022"},{"key":"2234_CR28","unstructured":"MedDRA. MedDRA Hierarchy | MedDRA. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy. Accessed 3 September 2021"},{"key":"2234_CR29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting: QUANTITATIVE SIGNAL DETECTION. Pharmacoepidem Drug Safe 18:427\u2013436","journal-title":"Pharmacoepidem Drug Safe"},{"key":"2234_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"2234_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"J-L Faillie","year":"2019","unstructured":"Faillie J-L (2019) Case\u2013non-case studies: principle, methods, bias and interpretation. Therapies 74:225\u2013232","journal-title":"Therapies"},{"key":"2234_CR32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11920-010-0113-y","volume":"12","author":"A Francis","year":"2010","unstructured":"Francis A (2010) Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 12:180\u2013185","journal-title":"Curr Psychiatry Rep"},{"key":"2234_CR33","unstructured":"Record growth pushes VigiBase past 28 million reports. Uppsala Reports. 20211110. https:\/\/www.uppsalareports.org\/articles\/record-growth-pushes-vigibase-past-28-million-reports\/. Accessed 12 April 2023"},{"key":"2234_CR34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2215-0366(19)30190-7","volume":"6","author":"JP Rogers","year":"2019","unstructured":"Rogers JP, Pollak TA, Blackman G, David AS (2019) Catatonia and the immune system: a review. Lancet Psychiatry 6:620\u2013630","journal-title":"Lancet Psychiatry"},{"key":"2234_CR35","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2022.30","author":"AS Dawood","year":"2022","unstructured":"Dawood AS, Dawood A, Dawood S (2022) Catatonia after COVID-19 infection: scoping review. BJPsych Bull. https:\/\/doi.org\/10.1192\/bjb.2022.30","journal-title":"BJPsych Bull"},{"key":"2234_CR36","doi-asserted-by":"crossref","first-page":"fcab169","DOI":"10.1093\/braincomms\/fcab169","volume":"3","author":"CH G\u00f6bel","year":"2021","unstructured":"G\u00f6bel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A et al (2021) Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 3:fcab169","journal-title":"Brain Commun"},{"key":"2234_CR37","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/978-1-4614-4788-7_108","volume-title":"Comprehensive guide to autism","author":"V Bambini-Junior","year":"2014","unstructured":"Bambini-Junior V, Baronio D, MacKenzie J, Zanatta G, dos Riesgo RS, Gottfried C (2014) Prenatal exposure to valproate in animals and autism. In: Patel VB, Preedy VR, Martin CR (eds) Comprehensive guide to autism. Springer, New York, pp 1779\u20131793"},{"key":"2234_CR38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1469-8749.1997.tb07500.x","volume":"39","author":"PG Williams","year":"1997","unstructured":"Williams PG, Hersh JH (1997) A male with fetal valproate syndrome and autism. Dev Med Child Neurol 39:632\u2013634","journal-title":"Dev Med Child Neurol"},{"key":"2234_CR39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0033-3182(93)71938-6","volume":"34","author":"L Bernstein","year":"1993","unstructured":"Bernstein L, Levin R (1993) Catatonia responsive to intravenous lorazepam in a patient with cyclosporine neurotoxicity and hypomagnesemia. Psychosomatics 34:102\u2013103","journal-title":"Psychosomatics"},{"key":"2234_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-019-2107-6","volume":"19","author":"RD Heekin","year":"2019","unstructured":"Heekin RD, Bradshaw K, Calarge CA (2019) First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome. BMC Psychiatry 19:123","journal-title":"BMC Psychiatry"},{"key":"2234_CR41","unstructured":"Cyclosporine-Associated Neurotoxicity | Circulation. https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.94.6.1209. Accessed 22 December 2022"},{"key":"2234_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/921253","volume":"2013","author":"DM Youssef","year":"2013","unstructured":"Youssef DM, Abdelsalam MM, Abozeid AM, Youssef UM (2013) Assessment of behavior abnormalities of corticosteroids in children with nephrotic syndrome. ISRN Psychiatry 2013:1\u20136","journal-title":"ISRN Psychiatry"},{"key":"2234_CR43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.mayocp.2014.01.010","volume":"89","author":"LB Drozdowicz","year":"2014","unstructured":"Drozdowicz LB, Bostwick JM (2014) Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clinic Proc. 89:817\u2013834","journal-title":"Mayo Clinic Proc."},{"key":"2234_CR44","unstructured":"FDA-Approved Drugs: Risperdal. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020272. Accessed 17 September 2022"},{"key":"2234_CR45","unstructured":"EMA. Risperdal. European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/risperdal. Accessed 17 September 2022"},{"key":"2234_CR46","unstructured":"EMA. Haldol and associated names. European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/haldol-associated-names. Accessed 22 December 2022"},{"key":"2234_CR47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/jnp.2009.21.4.371","volume":"21","author":"DJ Catatonia","year":"2009","unstructured":"Catatonia DJ (2009) Clinical aspects and neurobiological correlates. JNP 21:371\u2013380","journal-title":"JNP"},{"key":"2234_CR48","first-page":"bcr2014204154","volume":"2014","author":"R Dosi","year":"2014","unstructured":"Dosi R, Ambaliya A, Joshi H, Patell R (2014) Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. Case Reports 2014:bcr2014204154","journal-title":"Case Reports"},{"key":"2234_CR49","volume":"14","author":"S Prakash","year":"2021","unstructured":"Prakash S, Lodha D, Rawat KS (2021) Coexistence of serotonin syndrome and neuroleptic malignant syndrome: does it exist? BMJ Case Reports CP 14:e241578","journal-title":"BMJ Case Reports CP"},{"key":"2234_CR50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/0972-6748.151703","volume":"23","author":"MK Sahoo","year":"2014","unstructured":"Sahoo MK, Agarwal S, Biswas H (2014) Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment. Ind Psychiatry J 23:163\u2013165","journal-title":"Ind Psychiatry J"},{"key":"2234_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e3181c9bfe6","volume":"30","author":"JWY Lee","year":"2010","unstructured":"Lee JWY (2010) Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 30:3\u201310","journal-title":"J Clin Psychopharmacol"},{"key":"2234_CR52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/cap.2016.0180","volume":"27","author":"N Ghaziuddin","year":"2017","unstructured":"Ghaziuddin N, Hendriks M, Patel P, Wachtel LE, Dhossche DM (2017) Neuroleptic malignant syndrome\/malignant catatonia in child psychiatry: literature review and a case series. J Child Adolesc Psychopharmacol 27:359\u2013365","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2234_CR53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/appi.neuropsych.17060123","volume":"30","author":"JR Llesuy","year":"2018","unstructured":"Llesuy JR, Medina M, Jacobson KC, Cooper JJ (2018) Catatonia under-diagnosis in the general hospital. JNP 30:145\u2013151","journal-title":"JNP"},{"key":"2234_CR54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","volume":"6","author":"SA Rasmussen","year":"2016","unstructured":"Rasmussen SA, Mazurek MF, Rosebush PI (2016) Catatonia: our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry 6:391\u2013398","journal-title":"World J Psychiatry"},{"key":"2234_CR55","first-page":"1951965","volume":"2017","author":"J Park","year":"2017","unstructured":"Park J, Tan J, Krzeminski S, Hazeghazam M, Bandlamuri M, Carlson RW (2017) Malignant catatonia warrants early psychiatric-critical care collaborative management: two cases and literature review. Case Rep Crit Care 2017:1951965","journal-title":"Case Rep Crit Care"},{"key":"2234_CR56","doi-asserted-by":"crossref","first-page":"44592","DOI":"10.4088\/JCP.21m14238","volume":"84","author":"JD Costa","year":"2022","unstructured":"Costa JD, Very E, Vanessa Rousseau P, Virolle J, Redon M, Ta\u00efb S et al (2022) Comparative effects of 30 antipsychotics on risk of catatonia: an analysis of the WHO Pharmacovigilance Database. J Clin Psychiatry 84:44592","journal-title":"J Clin Psychiatry"},{"key":"2234_CR57","first-page":"325","volume":"37","author":"VF Donnoli","year":"1991","unstructured":"Donnoli VF (1991) [Akinetic catatonia and antidepressants]. Acta Psiquiatr Psicol Am Lat 37:325\u2013327","journal-title":"Acta Psiquiatr Psicol Am Lat"},{"key":"2234_CR58","unstructured":"Benzatropine\/chlorpromazine\/haloperidol: Neuroleptic malignant syndrome: case report - ProQuest. https:\/\/www.proquest.com\/openview\/7aa331928343231531553bb71364bcb5\/1?pq-origsite=gscholar&cbl=43703. Accessed 22 December 2022"},{"key":"2234_CR59","unstructured":"Benzatropine. https:\/\/go.drugbank.com\/drugs\/DB00245. Accessed 22 December 2022"},{"key":"2234_CR60","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-023-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-023-02234-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-023-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:08:07Z","timestamp":1715857687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-023-02234-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s00787-023-02234-4","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors do declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics committee approval was not required for this observational study because the analysis was carried out on an anonymized pharmacovigilance database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}